Asthma: Phenotyping Exacerbations 3 (APEX3)

Exacerbations of asthma (asthma attacks) are very common in the UK. They are frightening for patients, expensive for the health service, and occasionally lead to avoidable deaths.

Despite the obvious importance of asthma attacks, they remain poorly understood. Although some of the triggers for attacks are known, the resultant characteristics of attacks are not. Recent research has shown different inflammation profiles associated with asthma attacks; however, this is not well understood, and all asthma attacks are treated the same. Increased knowledge about the nature of asthma attacks may better define these attacks and help develop more targeted treatment options.

This study aims to describe the characteristics of patients admitted with asthma attacks. The recovery and response to standard treatment for asthma attacks following discharge from the hospital will also be described.

This is achieved by studying the characteristics of asthma attacks in patients hospitalized with acute asthma. Participants will be asked to attend two follow-up visits during which their response to treatment will be described.

The study is planned to last for 2.5 years, with a recruitment period of 18 months, and will include 100 participants with acute asthma.

Study Overview

• Status: Recruiting
• Conditions: Asthma Attack
• Intervention / Treatment: Diagnostic test: Spirometry including peak flow; Diagnostic test: Fractional Exhaled Nitric Oxide (FeNO); Diagnostic test: Forced Oscillation Technique (FOT); Procedure: Sputum Induction; Diagnostic test: Bloods; Diagnostic test: Nasal lavage; Diagnostic test: Throat swab; Diagnostic test: Nasal Brush.; Diagnostic test: Nasal absorption; Other: Medical History, Demographic, and Concomitant Medications; Other: Sino-nasal Outcome Test; Other: Gastroesophageal Reflux Disease Questionnaire; Other: Pittsburgh Vocal Cord Dysfunction Index; Other: Nijmegen Questionnaire.; Other: Hospital Anxiety and Depression Scale; Other: Compliance and adherence; Other: Acute Asthma Quality of Life Questionnaire

Detailed Description

Asthma is a common condition affecting 9.8 million people in the United Kingdom1. Asthma attacks cause nearly 1500 deaths per year in the UK2 and account for over 90,000 hospital admissions and 1800 intensive care admissions costing at least 1 billion pounds a year3.

Non-asthma conditions such as Vocal Cord Dysfunction4 and Dysfunctional Breathing Pattern5 can mimic severe asthma and lead to hospital admission and inappropriate asthma treatment with potentially harmful high dose corticosteroids. However, the proportion of patients admitted with these asthma mimics is unclear.

The use of biomarkers to guide treatment in stable asthma is now commonplace, but this prospect has not been fully explored in acute asthma attacks. Determining the type of inflammation underlying an attack can, however be tricky because many patients receive oral corticosteroid prior to, or soon after admission, which promptly and markedly affects the most accessible type 2 asthma (T2) biomarkers7, the blood eosinophil count. Measurement of another T2 biomarker, fractional exhaled nitric oxide (FENO), during an attack may prove a useful measure of ongoing T2 airway inflammation, but this strategy requires assessment.

Airway obstruction in asthma attacks is assessed and confirmed by measuring peak expiratory flow and/or forced expiratory volumes. These measures are effort-dependent and can, therefore, be unreliable and misleading if improperly performed. We aim to evaluate the potential feasibility and utility of alternative diagnostic methods of assessing airway obstruction and measuring T2 biomarkers to see if these allow the distinction between actual asthma attacks and asthma attack mimics and also if they can distinguish different types of asthma attacks.

The pattern of recovery following asthma attacks is also not fully understood. Studies have reported varying recovery times8 and inconsistencies in the response of airway obstruction9 and T2 biomarkers10 to corticosteroid treatment in acute asthma.

The investigators hypothesise that a significant proportion of patients admitted to hospital with suspected asthma attacks have an alternate cause for their clinical presentation. To further explore this, The investigators propose an observational study to describe and investigate the characteristics of patients admitted with suspected severe asthma. The investigators will assess the utility of point of care, non-invasive biomarker measurements in identifying pulmonary and extrapulmonary traits in patients hospitalised due to presumed asthma attack. A variety of study assessments will be performed at the baseline visit (exacerbation visit), and two follow up visits following hospital discharge. Results of study assessments obtained during each study visit will be compared and analysed. This is the first study to prospectively investigate acute asthma both during and following exacerbation episodes. This will allow a comprehensive understanding and description of pulmonary and extrapulmonary traits as well as the pattern of recovery following asthma attacks.

• Study Type: Observational
• Enrollment (Anticipated): 100

Contacts and Locations

• Study Contact: Name: Mouaid Aljehani; Phone Number: 78014 +44 115 969 1169; Email: Mouaid.Aljehani@nottingham.ac.uk
• Study Contact Backup: Name: Elizabeth Dark; Phone Number: 78001 +44 115 969 1169; Email: Elizabeth.Dark@nuh.nhs.uk

Study Locations

• United Kingdom
  • Nottinghamshire
    • Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
      • Recruiting
      • Nottingham University Hospital
      • Contact: Elizabeth Dark; Phone Number: 78001 +44 115 969 1169; Email: Elizabeth.Dark@nuh.nhs.uk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients admitted to hospital with suspected asthma attacks.

Description

Inclusion Criteria:

• The ability to give fully informed consent
• Male or female aged ≥ 18 years of age.
• Admission with a suspected acute asthma attack.
• Able (in the investigator's opinion) and willing to comply with clinical investigation requirements.

Exclusion Criteria:

• Other clinically significant respiratory diseases including predominant Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis.
• Any other clinically significant medical disease or uncontrolled concomitant disease that is likely, in the investigator's opinion, to impact the ability to participate in the study or the study results.
• Pregnant women, lactating women or women who are planning to become pregnant.
• Investigator determined apparent other cause for admission.
• Acute COVID infection.
• Non-English-speaking participants who are unable to comprehend the reasons for the study due to limitations in understanding the English language

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort

Intervention / Treatment

Asthma Attack patients.; Patients admitted with Asthma Attacks.

Diagnostic test: Spirometry including peak flow; Spirometry including peak flow to assess the degree of airway obstruction. Spirometry will be conducted according to a study SOP. The Global Lung Function (GLI) 2012 equations will be used. Reversibility testing will not be routinely performed. Thus, asthma medications will not normally be withheld for study visits and patients should take their inhalers as usual. The same type of device will be used at each visit.; Diagnostic test: Fractional Exhaled Nitric Oxide (FeNO); Fractional Exhaled Nitric Oxide (FeNO) to assess the degree of airway inflammation. FeNO will be measured using a standard device (NIOXX Vero®) in accordance with the manufacturer's guidelines. The same type of device will be used at each visit. FeNO should be performed prior to any other respiratory assessment if possible.; Diagnostic test: Forced Oscillation Technique (FOT); FOT is a non-invasive method that evaluates resistance and reactance in the respiratory system during tidal breathing. It should be performed after FeNO, but prior to Spirometry and will be conducted according to a study SOP.; Procedure: Sputum Induction; Sputum Induction for the assessment of airway inflammation and microbiology. Sputum induction will be performed according to an SOP, which includes measures to protect the safety of participants. These consist of pre-treatment with Salbutamol, a short acting bronchodilator, stipulated levels of lung function in order to perform the test and stopping criteria. If the participant is unable to undergo the procedure, due to safety reasons, they will be asked to produce a spontaneous sputum sample. Sputum samples will be collected for a differential cell count, bacterial culture and sensitivity and storage for future research. Procedures for sampling and processing will be detailed in a study SOP.; Diagnostic test: Bloods; Blood will be collected for laboratory analysis, including Vitamin D, Haematology, WCC differential, C-Reactive protein.; Diagnostic test: Nasal lavage; Nasal lavage samples will be taken at the baseline (attack) visit. Samples will be obtained by injecting 5ml of sterile normal saline into the participant's nostrils via a nasal adaptor and then immediately aspirated. These will be placed in a sterile container and transported to the laboratory for viral identification. This procedure will be detailed in a study SOP.; Diagnostic test: Throat swab; A throat swab will be taken at the baseline (attack) visit for viral identification.; Diagnostic test: Nasal Brush.; Nasal brushings samples may be taken at baseline (attack) and at second visits for RNA and DNA extraction. This will be optional and specific consent from participants will be sought. Procedures for sampling and processing will be detailed in a study SOP.; Diagnostic test: Nasal absorption; Nasal absorption will be used to collect mucosal lining fluid from the respiratory tract for cytokines profiling at baseline (attack) and at second visits.; Other: Medical History, Demographic, and Concomitant Medications; Medical history will include clinically significant diseases and prior surgeries and smoking history. A specific respiratory history will also be recorded. Demographic data will include age, sex and self- reported race/ethnicity. Medication use will also be collected.; Other: Sino-nasal Outcome Test; The incidence of upper airway symptoms will be assessed using Sino-nasal Outcome Test (SNOT).; Other: Gastroesophageal Reflux Disease Questionnaire; The incidence of Gastroesophageal Reflux Disease will be assessed using GERDQ questionnaire.; Other: Pittsburgh Vocal Cord Dysfunction Index; The incidence of vocal cord dysfunction will be assessed using Pittsburgh Vocal Cord Dysfunction (VCD) Index; Other: Nijmegen Questionnaire.; The incidence of dysfunctional breathing will be assessed using Nijmegen dysfunctional questionnaire.; Other: Hospital Anxiety and Depression Scale; The incidence of anxiety and depression will be assessed using Hospital Anxiety and Depression Scale (HADS).; Other: Compliance and adherence; In order to assess adherence as a factor in exacerbations, a participant's beliefs and attitudes towards medicines will be explored using the Medicines Adherence Report Scale (MARS) questionnaire. Non-intentional non-compliance with usual treatment will be assessed by checking inhaler technique; poor inhaler technique will be reported to the participant's clinical team. Also, GP records will be reviewed for information on medications prescribed in the last 12 months.; Other: Acute Asthma Quality of Life Questionnaire; The impact of acute asthma on quality of life will be assessed using Acute Asthma Quality of Life Questionnaire at baseline and follow up.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of cytokine levels in nasal lining fluid at attack and recovery visits	Nasal absorption will be used to collect mucosal lining fluid from the respiratory tract for cytokines profiling at baseline (attack) and at second visits.	14 days
The measurement of vitamin D levels in the blood on admission to the hospital	vitamin D levels in the blood on admission to the hospital	baseline
Assessment of evidence of infection: sputum for bacterial culture and sensitivity (MC&S).	Assessment of evidence of infection: sputum for bacterial culture and sensitivity (MC&S).	14 days
Assessment of evidence of infection: CRP.	Assessment of evidence of infection: CRP.	14 days
Assessment of evidence of infection: Throat swab/nasal lavage for viral PCR.	Assessment of evidence of infection: Throat swab/nasal lavage for viral PCR.	baseline
A specific asthma history (polypharmacy, previous asthma attacks, triggers, Personalised Asthma Action Plan) for the assessment of risk factor for attack.	Assessment of risk factor for attack	baseline
Assessment of adherence to medications (MARS, prescription records, inhaler technique) for the assessment of behavioural attack traits.	Assessment of behavioural attack traits.	baseline
Assessment of airway obstruction at attack and recovery visits using peak expiratory flow rate (PEFR).	Assessment of airway obstruction	14 days
Assessment of airway obstruction at attack and recovery visits using spirometry.	Assessment of airway obstruction	14 days
Assessment of airway obstruction at attack and recovery visits using Forced Oscillation Technique (FOT).	Assessment of airway obstruction	14 days
Assessment of airway obstruction at attack using physician recorded expiratory wheeze	Assessment of airway obstruction	baseline
Assessment of airway inflammation at attack and recovery visits using Fractional Exhaled Nitric Oxide (FeNO).	Assessment of airway inflammation	14 days
Assessment of airway inflammation at attack and recovery visits using sputum inflammatory cell count.	Assessment of airway inflammation	14 days
Assessment of airway inflammation at attack and recovery visits using blood eosinophil count.	Assessment of airway inflammation	14 days
Assessment of symptom burden at attack and recovery visits using the Acute AQLQ questionnaire	Assessment of symptom burden	28 days
Assessment of Body Mass Index BMI.	Assessment of Body Mass Index BMI.	baseline
Assessment of the incidence of upper airway symptoms.	The incidence of upper airway symptoms will be assessed using the Sino-nasal Outcome Test (SNOT).	baseline
The assessment of the incidence of Gastroesophageal Reflux Disease.	The assessment of the incidence of Gastroesophageal Reflux Disease using the GERDQ questionnaire.	baseline
The assessment of the incidence of vocal cord dysfunction	The assessment of the incidence of vocal cord dysfunction using the Pittsburgh Vocal Cord Dysfunction (VCD) Index.	baseline
The assessment of the incidence of dysfunctional breathing	The assessment of the incidence of dysfunctional breathing using the Nijmegen dysfunctional questionnaire.	baseline
The assessment of the incidence of anxiety and depression	The assessment of the incidence of anxiety and depression using the Hospital Anxiety and Depression Scale (HADS).	baseline

Collaborators and Investigators

• Sponsor: University of Nottingham
• Investigators: Principal Investigator: Matthew Martin, The University of Nottingham

Study record dates

Study Major Dates

• Study Start (Actual): May 9, 2022
• Primary Completion (Anticipated): December 31, 2023
• Study Completion (Anticipated): December 31, 2023

Study Registration Dates

• First Submitted: May 26, 2022
• First Submitted That Met QC Criteria: June 30, 2022
• First Posted (Actual): July 6, 2022

Study Record Updates

• Last Update Posted (Actual): July 6, 2022
• Last Update Submitted That Met QC Criteria: June 30, 2022
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Immune System Diseases; Lung Diseases; Hypersensitivity, Immediate; Bronchial Diseases; Lung Diseases, Obstructive; Respiratory Hypersensitivity; Hypersensitivity; Asthma; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Vasodilator Agents; Autonomic Agents; Peripheral Nervous System Agents; Protective Agents; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Antioxidants; Free Radical Scavengers; Endothelium-Dependent Relaxing Factors; Gasotransmitters; Nitric Oxide
• Other Study ID Numbers: 304615-21066

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided
• IPD Plan Description: No plans yet.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No